Discussion
AD is characterised by the gradual loss of memory, cognition and activities of daily life.12 The disease of the patient of interest progressed rapidly, and her overall cognitive functions were impaired within 2 years. The main symptoms were a severe decline in memory and an almost total loss of comprehension ability and executive ability within 2 years, acompanied by aphasia, loss of recognition,disuse. According to the results of the brain MRI, it was found that there was evidence of brain atrophy which was significant in the frontal cortex and a fourth-degree atrophy detected in the coronal hippocampus. Furthermore, this patient has a positive family history of dementia and a 40-year history of hypertension. The genetic testing showed that there was a base change c.A479G in the third exon of ACE gene, and this base change caused its encoding protein’s 160th codon to be changed from aspartic to serine. The genotype of APOE gene was ɛ3/ɛ4, so the symptoms of this patient were considered to be related to the genetic mutation.
The main pathological feature of AD is the formation of toxic amyloid due to abnormal processing of the amyloid peptides of the amyloid precursor protein (APP). It is a type of amyloid deposit that eventually leads to the disease caused by extensive destruction of neurons in the brain, which is similar to abnormal cholesterol deposition causing atherosclerosis. The renin-angiotensin system (RAS) affects the blood vessels, metabolic homeostasis, amyloid metabolism, and learning and memory. As a key RAS protein, ACE contains many variant mega genes and codes associated with AD13 because ACE can degrade the β amyloid-like protein, which is a pathological symbol of AD, thereby inhibiting its aggregation. The level and active portion of ACE may be regulated by the insertion and deletion polymorphism of ACE gene.14 Recent evidence has indicated that AD has different vascular risk factors from other prevalent dementia types, and it may cause the deterioration of cerebrovascular function, thereby increasing neurodegeneration and premature neuronal deaths due to reduced cerebral perfusion.15 In the mouse model of AD, ACE 10/10 phenotype provides significant protection for AD pathology, including reducing inflammation, reducing the burden of neurotoxic amyloid-βprotein and maintaining cognitive functions. These studies have shown that in order to better protect against many different types of pathological damage, including cognitive decline observed in AD animal models, the increased monotype ACE expression in mice alters immune responses.16 ACE is widely expressed in the brain, so it may play a role in the pathogenesis of dementia.17
APOE mainly affects the pathogenesis of AD by affecting amyloid-like β protein, and the aggregation of substantial plaques and the β protein in cerebral amyloid angiopathy triggers neuroinflammation.18 In addition, APOE may affect neuroinflammation, cerebrovascular integrity, metabolism, synaptic plasticity and transcription directly with the independent mechanism of amyloid-like β protein.
The patient of interest in this article has a base change c.A479G on the third exon of the ACE gene, and this base change has caused the 160th codon of its encoding protein to change from aspartic to serine. This phenomenon may lead to the dysfunction in the RAS, which caused the patient to have high blood pressure for nearly 40 years. In the mean time, alterations in the ACE gene may lead to an increase in toxic brain amyloid deposition. On the other hand, because the aggregation of amyloid-like β protein in human brains follows the pattern of APOE4 > APOE3 > APOE2,19 the ɛ3/ɛ4 type of APOE gene in the patient promotes the aggregation of amyloid-like β protein, thereby further aggravating the neuroinflammation, leading to a significant decline in cognitive functions and the rapid progression of the disease.
This case cannot have regular follow-ups because the patient left the country soon after. Furthermore, it is hard to obtain blood samples from her family members to conduct genetic analysis, so we cannot explore whether the ACE gene and APOE gene exist in her family members or not, and it is also hard to track whether her family members suffer from EOAD or not.